A new mouse model of frailty: the Cu/Zn superoxide dismutase knockout mouse
Frailty is a geriatric syndrome that is an important public health problem for the older adults living in the USA. Although several methods have been developed to measure frailty in humans, we have very little understanding of its etiology. Because the molecular basis of frailty is poorly understood, mouse models would be of great value in determining which pathways contribute to the development of frailty. More importantly, mouse models would be critical in testing potential therapies to treat and possibly prevent frailty. In this article, we present data showing that Sod1KO mice, which lack the antioxidant enzyme, Cu/Zn superoxide dismutase, are an excellent model of frailty, and we compare the Sod1KO mice to the only other mouse model of frailty, mice with the deletion of the IL-10 gene. Sod1KO mice exhibit four characteristics that have been used to define human frailty: weight loss, weakness, low physical activity, and exhaustion. In addition, Sod1KO mice show increased inflammation and sarcopenia, which are strongly associated with human frailty. The Sod1KO mice also show alterations in pathways that have been proposed to play a role in the etiology of frailty: oxidative stress, mitochondrial dysfunction, and cell senescence. Using Sod1KO mice, we show that dietary restriction can delay/prevent characteristics of frailty in mice.
KeywordsCu/Zn superoxide dismutase Frailty Inflammation Senescence Sarcopenia Oxidative stress
The frailty phenotype criteria and measurements in humans
Fried et al. (2001)
Studenski et al. (2004)
Weight loss (>10 lbs. lost unintentionally in prior year), sarcopenia (loss of muscle mass)
Grip strength: lowest 20% (by gender, body mass index)
3. Poor endurance and energy
Walking time/15 ft: slowest 20% (by gender, height)
5. Low physical activity level
Kcals/week: lowest 20% (by gender)
1. Strength (grip, upper, lower)
2. Balance (falls, fear of falling, balance performance)
3. Motor processing (coordination, movement planning, and speed)
4. Flexibility (stiffness, range of motion)
5. Nutrition (intake, weight, muscle mass, synthetic function)
6. Stamina (energy/fatigue, endurance)
7. Mobility (walking, transfers, stairs, devices)
8. Vulnerability (utilization, ability to tolerate stress)
9. Neurocognitive processing (alertness, attention, multi-tasking)
10. Self-perceived health
11. Life space (ability to leave room, home, neighborhood, community)
12. Activities of daily living (basic, instrumental, advanced)
13. Modifications (devices, frequency, or way of doing)
14. Role function (social, vocational)
15. Interest and motivation (interest in others, desire to take on activities)
16. Self-efficacy (confidence, locus of control)
17. Emotions (depression, anxiety)
18. Appearance (interest and awareness of grooming)
19. Behavior/personality (self vs. other orientation, irritability)
20. Social world (interest and interactions with others)
Frailty is thought to represent a distinct physiologic state in which individuals are highly vulnerable to external stressors and recover poorly from these, rarely reaching their previous baseline of health and function (Fried and Walston 2003), i.e., it is characterized by loss of resilience, increased vulnerability to stress, and a lack of physiological reserve. Currently, a large amount of evidence suggests that low-grade inflammation plays an important role in the etiology of frailty. The initial studies showing an association between frailty and inflammation were obtained with serum or plasma markers of inflammation, such as interleukin-6 (IL-6) and C-reactive protein (CRP). Walston et al. (2002) found in the Cardiovascular Health Study that frail individuals had increased mean levels of CRP compared to non-frail individuals (5.5 ± 9.8 vs. 2.7 ± 4.0 mg/L). These peripheral blood markers persisted after exclusion of individuals with cardiovascular disease and diabetes, as well as after adjustment for age, sex, and race. Subsequently, Leng et al. (2002) found in community-dwelling older adults that serum IL-6 levels were elevated over 50% in frail compared to non-frail older adults. These findings have been replicated by Barzilay et al. (2007). Qu et al. (2009) found that expression of a potent inflammatory chemokine, CXCL-10, by monocytes was increased in frail compared to non-frail elderly, and there was high correlation between monocyte CXCL-10 expression and serum IL-6 levels. In addition, they found that monocytes from frail individuals had twofold increased expression of inflammatory genes compared to non-frail individuals. More recently, Collerton et al. (2012) showed an association of IL-6, TNF-α, and CRP levels with frailty in a large cross-sectional cohort in Scotland that included 845 subjects >85 years of age.
It has been argued that the increased inflammation observed in frail older adults might arise from increased oxidative stress. Oxidative stress increases with age and multiple studies report an association between oxidative stress and frailty. Protein carbonyls, which are a result of oxidative damage to proteins, were shown in a cross-sectional study to be associated with poor handgrip strength (Howard et al. 2007), and serum protein carbonyl levels were found to be an independent predictor of gait speed decline in humans (Semba et al. 2007). High levels of isoprostanes, which are produced by lipid peroxidation, have been reported to predict death in older adults (Cesari et al. 2012). In 2009, two groups reported that high oxidative stress was correlated with frailty. Serviddio et al. (2009) found increased levels of oxidized glutathione and protein adducts of malonaldehyde and 4-hydroxy-2,3-nonenal in the plasma of frail patients. Wu et al. (2009) showed an association between a marker of oxidative DNA damage (8-oxo-deoxyguanosine) in the plasma and frailty in elderly Chinese. More recently, Ingles et al. (2014) reported that markers of oxidative stress in plasma (malonaldehyde and protein carbonylation) were related to frailty but not to age or sex in a geriatric population, and in the Framingham Offspring Study, Liu et al. (2016) reported that elevated levels of plasma isoprostanes were associated with increased risk of frailty and slower gait speed.
Mitochondrial dysfunction has been proposed to play a role in frailty because mitochondria are the major source of reactive oxygen species (ROS) and energy in the cell. Therefore, changes in the function of mitochondria leading to increased ROS generation or reduced ATP generation could lead to frailty. For example, the increased oxidative stress that has been observed in frail older adults has been hypothesized to arise from mitochondrial dysfunction (Villamena and Zweier 2004). Consistent with this hypothesis is the study by Baptista et al. (2012) showing that superoxide anion production was increased in white blood cells of frail older adults. Recently, it was also shown in blood that, lower mtDNA copy number, a marker that reveals mitochondrial depletion, energy reserves, and oxidative stress is associated with frailty (Ashar et al. 2015).
More recently, it has been proposed that cell senescence may play a role in frailty (Fedarko 2011; LeBrasseur et al. 2015). It is now well accepted that senescent cells increase with age in many mammalian tissues and are found at sites of age-related pathologies (for reviews see Coppé et al. 2010 and Rodier and Campisi 2011). In addition, Campisi’s laboratory has shown that senescent cells secrete biologically active proteins (e.g., growth factors, proteases, cytokines, and other factors) that have potent autocrine and paracrine activities (Coppe et al. 2008), a phenomenon termed the senescence-associated secretory phenotype (SASP). The SASP includes several potent inflammatory cytokines including IL-6, IL-1β, and IL-8, which may serve as an important source of low-level chronic inflammation (Chung et al. 2009). Therefore, it is possible that increased cell senescence in frail older adults might contribute to increased chronic inflammation and the frailty phenotype. Baker et al. (2011) published the first direct evidence showing that cell senescence is involved in aging in mice. Using a mouse model they developed in which senescent, p16Ink4a-positive cells were eliminated upon the administration of the drug, AP20187, they were able to test the effect of reducing/eliminating senescent cells on aging/pathology. AP20187 treatment delayed/reduced the development of age-associated deficits known to accompany cell senescence, e.g., sarcopenia and the loss of adipose tissue. Of particular importance to frailty was the effect of eliminating senescent cells on muscle. Muscle fiber diameters of the AP20187-treated mice were larger than those of untreated mice and treadmill exercise tests revealed that duration of exercise, distance traveled, and overall amount of work performed were all significantly increased in the mice treated with AP20187, indicating preservation of muscle function by the elimination of senescent cells. They also showed that improvements in skeletal muscle function could also be achieved by the clearance of p16Ink4a-positive senescent cells.
Animal models of frailty
Over the past two decades, the use of genetically modified mouse models to study human diseases has become very popular, e.g., the use of ApoE or LDL receptor knockout mice to model atherosclerosis, which does not occur in normal mice, or the use of transgenic mice that produce a mutant form of a gene that has been shown to be associated with a human disease, e.g., transgenic mice that overexpress mutated amyloid precursor protein (Alzheimer’s disease), mutant Cu/Zn superoxide dismutase (amyotrophic lateral sclerosis), or mutant huntingtin (Huntington’s disease). The major advantage of mouse models that mimic a human disease is that one can use mice to identify potential targets for developing therapies as well as the biological mechanism(s) underlying the disease to be defined.
Because the molecular basis of frailty, a syndrome rather than a disease, is poorly understood, mouse models of frailty would be of great value in determining what pathways contribute to the development of frailty. More importantly, a mouse model of frailty would give the geriatric research community a model to use in testing potential therapies to treat and possibly prevent frailty. This is particularly important in treating frailty because older, frail individuals are in poor health and have limited resilience capacity.
Interleukin-10 knockout mouse
Interleukin-10 (IL-10) was identified as a cytokine produced by type 2 T helper cells in 1990 (Moore et al. 1990), and IL-10−/− (IL-10KO) mice have been generated to study the physiological role of IL-10. Kuhn et al. (1993) showed that IL-10KO mice develop a chronic enterocolitis because of an aberrant immune response. Subsequently, it was found that knocking out IL-10 resulted in an increased activation of nuclear factor-kappa B (NFκB) induced inflammatory mediators (Rennick et al. 1995; Berg et al. 1996). Because IL-10KO mice showed increased inflammation and because inflammation was believed to play a major role in frailty, Walston et al. (2008) determined whether the IL-10KO mice exhibited a frailty phenotype. As would be expected, the IL-10KO mice showed increased serum levels of IL-6. Studying mice from 10 to 18 months of age, Walston et al. (2008) found that the IL-10KO mice showed a greater decrease in grip strength with increasing age than wild-type (WT) mice and 125 genes were differentially expressed in the skeletal muscle of 50-week-old IL-10KO and WT mice. No major differences in body weight or measures of activity were found. Walston’s group (Ko et al. 2012) subsequently compared IL-10KO and WT mice from 12 to 90 weeks of age and found that the levels of circulating pro-inflammatory cytokines, e.g., IFN-γ, IL-1β, IL-6, KC, and TNF-α, were elevated across age groups in the IL-10KO mice. They also found a significant difference in the mortality between the IL-10KO and WT mice; the median survival of the IL-10KO mice was ~21 months while less than 10% of the WT mice had died at this age. IL-10KO mice also show mitochondrial dysfunction as suggested by lower rates of ATP synthesis and higher levels of damaged mitochondria in skeletal muscle (Akki et al. 2014; Ko et al. 2016).
Cu/Zn superoxide dismutase (Sod1KO) knockout mouse
Cu/Zn superoxide dismutase (Cu/ZnSOD) is the major superoxide dismutase isozyme that catalyzes the conversion of superoxide anions to hydrogen peroxide. It is found in all cells and is localized in the cytosol and the intermembrane space of the mitochondria (Okado-Matsumoto and Fridovich 2001). In 1996, Reaume et al. generated mice null for CuZnSOD (Sod1KO) and reported that they appear normal at birth. However, Sod1KO females are almost totally infertile due to ovarian dysfunction (Ho et al. 1998; Matzuk et al. 1998), and the Sod1KO mice show very high levels of oxidative stress in various tissues and plasma (Muller et al. 2006). In 2005, Huang’s laboratory reported that Sod1KO mice show a decrease in lifespan of approximately 30% (Elchuri et al. 2005). In 2013, our group confirmed that the lifespan of Sod1KO mice was reduced, e.g., median lifespan was reduced ~25% from ~30 months for WT mice to ~22 months for Sod1KO mice (Zhang et al. 2013a). Because Elchuri et al. (2005) reported that more than 70% of the Sod1KO mice developed liver hyperplasia and hepatocellular carcinoma later in life, it was initially believed that the decrease in the lifespan of the Sod1KO mice was the result of the dramatic increase in hepatocellular carcinoma, which is rare in C57BL/6 mice. In a more recent study, we found that only about 30% of the Sod1KO mice developed hepatocellular carcinoma later in life (Zhang et al. 2013a). However, data from several studies show that Sod1KO mice exhibited various accelerated aging phenotypes [e.g., hearing loss (Keithley et al. 2005), cataracts (Olofsson et al. 2007), skin thinning and delayed wound healing (Iuchi et al. 2010), and loss of muscle mass (Muller et al. 2006)] suggesting that the reduced lifespan of Sod1KO mice is largely a result of accelerated aging. We also showed that dietary restriction, which is a manipulation that retards aging in rodents, increased the lifespan of the Sod1KO mice to that of normal WT mice (Zhang et al. 2013a). Thus, the current data indicate that the Sod1KO mice show an accelerated aging phenotype.
Comparison of frailty phenotypes in humans and mouse models of frailty
Grip strength reduced
Grip strength reduced
Grip and muscle strength reduced
No change in spontaneous cage activity
Reduced voluntary running wheel activity
Treadmill and rotarod performance reduced
Increased levels of IL-6, CRP, CXCL-10, and TNF-α
Increased levels of IL-6, IFN-γ, IL-1β, KC, and TNF-α
Increased levels of IL-6, GM-CSF, Eotaxin, and KC
Although the IL-10KO and Sod1KO mouse models are currently the best mouse models of frailty available, there is always the question of how accurately deleting IL-10 or Sod1 replicates frailty because there is no evidence that the expression of either of these genes plays a role in frailty in humans. In addition, these mice develop special pathologies normally not observed in the WT mice, e.g., chronic enterocolitis in the IL-10KO mice and hepatocellular carcinoma in about one third of the Sod1KO mice. Nevertheless, the IL-10KO and Sod1KO mouse models give investigators the first tools for studying the mechanism underlying frailty and testing interventions to delay/prevent frailty. Important information about frailty has already been gained from these models. For example, they have provided direct evidence for inflammation playing an important role in frailty. The data by Walston et al. (2008) with IL-10KO mice in which inflammation is induced demonstrates that inflammation most likely plays a causative role in frailty. Our data showing that Sod1KO mice have increased inflammation also support the concept that inflammation plays a role in the etiology of frailty. In addition, the Sod1KO mouse model provides our first insight into how frailty might be prevented/delayed. Frailty in Sod1KO mice is attenuated by dietary restriction, e.g., dietary restriction reversed the loss of muscle mass and function and improved mitochondria function (Jang et al. 2012) and attenuated the increase in oxidative damage, cell senescence, and circulating levels of IL-6 (Zhang et al. 2017). These data are supported by a recent study from Kane et al. (2016) showing that 6 months of dietary restriction improved the frailty index score of 24-month-old WT mice.
In summary, the IL-10KO and Sod1KO mouse models give investigators the first animal models that can be used to study frailty. These mouse models allow investigators to use genetic approaches to identify the pathways that can lead to frailty as well as determine which tissues are key in the development of frailty. Because these two models induce frailty through different pathways (e.g., immune dysfunction for the IL-10KO mice and increased oxidative stress in the Sod1KO mice), they are complementary and a combination of these models will give investigators a robust approach to identifying the biological processes underlying frailty. In addition, the use of conditional Sod1KO models allow the investigators to study the effect of the tissue-specific deletion of Cu/Zn superoxide dismutase on frailty. Sod1flox/flox have been generated (Zhang et al. 2013b) and used to study the role of the muscle and motor neurons in sarcopenia (Zhang et al. 2013b; Sataranatarajan et al. 2015).
The research described above on the Sod1KO mice were generated over the past decade on program project grants from the National Institute on Aging to Drs. Brooks, Jackson, McArdle, Richardson, and Van Remmen (P01-AG020591 and P01-AG051442). Richardson and Van Remmen are supported by Senior Research Scientist Career awards from the Department of Veterans Affairs.
|Funder Name||Grant Number||Funding Note|
|National Institute on Aging|
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.